Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
Pain ; 165(7): e65-e79, 2024 Jul 01.
Article in English | MEDLINE | ID: mdl-38900144

ABSTRACT

ABSTRACT: Recent evidence highlights the importance of the neuroimmune interface, including periphery-to-central nervous system (CNS) neuroimmune crosstalk, in chronic pain. Although neuroinflammatory processes have been implicated in central sensitization for a long time, their potential neuroprotective and analgesic effects remain relatively elusive. We have explored the relationships between cytokine expression and symptom severity, and candidates for periphery-to-CNS crosstalk. Patients with degenerative disk disease (DDD) (nociceptive pain) or patients with lumbar disk herniation (LDH) with radiculopathy (predominantly neuropathic pain) completed questionnaires regarding pain and functional disability, underwent quantitative sensory testing, and provided blood and cerebrospinal fluid (CSF) samples. Proximity extension assay (PEA) was used to measure the levels of 92 inflammatory proteins in the CSF and serum from a total of 160 patients and controls, and CSF/serum albumin quotients was calculated for patients with DDD and patients with LDH. We found signs of neuroimmune activation, in the absence of systemic inflammation. Regarding periphery-to-CNS neuroimmune crosstalk, there were significant associations between several cytokines and albumin quotient, despite the latter being primarily at subclinical levels. The cytokines CCL11, CD5, IL8, and MMP-10 were elevated in the CSF, had positive correlations between CSF and serum levels, and associated in a nonlinear manner with back, but not leg, pain intensity in the LDH, but not the DDD, group. In conclusion, we found evidence for neuroimmune activation in the CNS of both patient groups in the absence of systemic inflammation and signs of a communication between CSF and serum. Complex and disease-specific associations were found between cytokines in CSF and back pain intensity.


Subject(s)
Chronic Pain , Cytokines , Intervertebral Disc Degeneration , Intervertebral Disc Displacement , Humans , Male , Female , Cytokines/cerebrospinal fluid , Cytokines/blood , Middle Aged , Intervertebral Disc Displacement/cerebrospinal fluid , Intervertebral Disc Displacement/complications , Intervertebral Disc Displacement/immunology , Intervertebral Disc Degeneration/cerebrospinal fluid , Intervertebral Disc Degeneration/immunology , Adult , Chronic Pain/cerebrospinal fluid , Chronic Pain/immunology , Chronic Pain/blood , Aged , Lumbar Vertebrae , Pain Measurement/methods , Neuroimmunomodulation/physiology
2.
J Neuroimmunol ; 344: 577249, 2020 07 15.
Article in English | MEDLINE | ID: mdl-32361148

ABSTRACT

INTRODUCTION: Patients with neuropathic pain have altered proteomic and neuropeptide constituents in cerebrospinal fluid (CSF) compared to controls. Tonic spinal cord stimulation (SCS) has demonstrated differential expression of neuropeptides in CSF before and after treatment suggesting potential mechanisms of action. Burst-SCS is an evidence-based paraesthesia free waveform utilised for neuropathic pain with a potentially different mechanistic action to tonic SCS. This study examines the dynamic biological changes of CSF at a cellular and proteome level after Burst-SCS. METHODS: Patients with neuropathic pain selected for SCS had CSF sampled prior to implant of SCS and following 8 weeks of continuous Burst-SCS. Baseline and 8-week pain scores with demographics were recorded. T cell frequencies were analysed by flow cytometry, proteome analysis was performed using mass spectrometry and secreted cytokines, chemokines and neurotrophins were measured by enzyme-linked immunosorbent assay (ELISA). RESULTS: 4 patients (2 females, 2 males) with a mean age of 51 years (+/-SEM 2.74, SD 5.48) achieved a reduction in pain of >50% following 8 weeks of Burst-SCS. Analysis of the CSF proteome indicated a significant alteration in protein expression most related to synapse assembly and immune regulators. There was significantly lower expression of the proteins: growth hormone A1 (PRL), somatostatin (SST), nucleobindin-2 (NUCB2), Calbindin (CALB1), acyl-CoA binding protein (DBI), proSAAS (PCSK1N), endothelin-3 (END3) and cholecystokinin (CCK) after Burst-SCS. The concentrations of secreted chemokines and cytokines and the frequencies of T cells were not significantly changed following Burst-SCS. CONCLUSION: This study characterised the alteration in the CSF proteome in response to burst SCS in vivo. Functional analysis indicated that the alterations in the CSF proteome is predominately linked to synapse assembly and immune effectors. Individual protein analysis also suggests potential supraspinal mechanisms.


Subject(s)
Chronic Pain/cerebrospinal fluid , Chronic Pain/therapy , Neuralgia/cerebrospinal fluid , Neuralgia/therapy , Proteome/metabolism , Spinal Cord Stimulation/methods , Biomarkers/cerebrospinal fluid , Biomarkers/metabolism , CD8-Positive T-Lymphocytes/metabolism , Chronic Pain/genetics , Cohort Studies , Female , Humans , Male , Middle Aged , Neuralgia/genetics , Pilot Projects , Proteome/genetics , Treatment Outcome
3.
BMC Anesthesiol ; 20(1): 69, 2020 03 25.
Article in English | MEDLINE | ID: mdl-32213162

ABSTRACT

BACKGROUND: Chronic osteoarthritic pain is not well understood in terms of its pathophysiological mechanism. Activated glial cells are thought to play a role in the maintenance of chronic pain. T98G glioblastoma cell line was previously observed to release higher amounts of interleukin-6 (IL-6) when treated with cerebrospinal fluid (CSF) from patients with another chronic pain condition, post-herpetic neuralgia. In this study, we investigated the ability of CSF from patients diagnosed with knee osteoarthritis suffering from chronic pain, to trigger the release of pro-inflammatory cytokines, IL-6, IL-1beta and tumour necrosis factor alpha (TNF-α) from T98G. Characterization of upstream signalling was also explored. METHODS: Fifteen osteoarthritis patients undergoing total knee replacement due to chronic knee pain and 15 patients without pain undergoing other surgeries with spinal anaesthesia were prospectively recruited. CSF was collected during anaesthesia. CSF were added to cultured T98G cells in the presence of lipopolysaccharide. IL-6, IL-1ß and TNF-α release from T98G cells were measured using enzyme immunoassay. Antibody array and western blotting were performed using CSF-triggered T98G cell lysates to identify possible signalling targets. Age, gender and pain scores were recorded. Mann-Whitney U test was used to compare IL-6 release and protein expression between groups. Association between IL-6 and pain score was analysed using linear regression. RESULTS: Significant higher levels of IL-6 were released by T98G cells when induced by osteoarthritis patients' CSF in the presence of LPS. The IL-6 levels showed positive association with pain score (adjusted B estimate = 10.1 (95% Confidence Interval 4.3-15.9); p = 0.001). Antibody array conducted with 6 pooled T98G cell lysate induced with osteoarthritis pain patient CSF identified greater than 2-fold proteins including STE20-related kinase adaptor protein and spleen tyrosine kinase. Further validation done using western blotting of individual CSF-triggered T98G cell lysate showed non-significant increase. CONCLUSION: Higher IL-6 release from T98G when triggered by OA-CSF, in the presence of LPS, suggest the presence of "unknown molecule" in CSF that may be crucial in the maintenance phase of chronic pain in our osteoarthritis population. Further studies on the signalling pathways involved in pain and relevance of IL-6 release from T98G cells in other pain models are needed.


Subject(s)
Chronic Pain/cerebrospinal fluid , Interleukin-6/metabolism , Neuroglia/metabolism , Osteoarthritis, Knee/cerebrospinal fluid , Arthroplasty, Replacement, Knee , Cell Line , Cells, Cultured , Female , Humans , Interleukin-1beta/metabolism , Male , Middle Aged , Osteoarthritis, Knee/surgery , Prospective Studies , Tumor Necrosis Factor-alpha/metabolism
4.
Pain ; 158(12): 2487-2495, 2017 Dec.
Article in English | MEDLINE | ID: mdl-28930774

ABSTRACT

Animal models suggest that chemokines are important mediators in the pathophysiology of neuropathic pain. Indeed, these substances have been called "gliotransmitters," a term that illustrates the close interplay between glial cells and neurons in the context of neuroinflammation and pain. However, evidence in humans is scarce. The aim of the study was to determine a comprehensive cerebrospinal fluid (CSF) inflammatory profile of patients with neuropathic pain. Our hypothesis was that we would thereby find indications of a postulated on-going process of central neuroinflammation. Samples of CSF were collected from 2 cohorts of patients with neuropathic pain (n = 11 and n = 16, respectively) and healthy control subjects (n = 11). The samples were analyzed with a multiplex proximity extension assay in which 92 inflammation-related proteins were measured simultaneously (Proseek Multiplex Inflammation I; Olink Bioscience, Uppsala, Sweden). Univariate testing with control of false discovery rate, as well as orthogonal partial least squares discriminant analysis, were used for statistical analyses. Levels of chemokines CXCL6, CXCL10, CCL8, CCL11, CCL23 in CSF, as well as protein LAPTGF-beta-1, were significantly higher in both neuropathic pain cohorts compared with healthy controls, pointing to neuroinflammation in patients. These 6 proteins were also major results in a recent similar study in patients with fibromyalgia. The findings need to be confirmed in larger cohorts, and the question of causality remains to be settled. Because it has been suggested that prevalent comorbidities to chronic pain (eg, depression, anxiety, poor sleep, and tiredness) also are associated with neuroinflammation, it will be important to determine whether neuroinflammation is a common mediator.


Subject(s)
Chemokines/cerebrospinal fluid , Chronic Pain/cerebrospinal fluid , Inflammation/cerebrospinal fluid , Neuralgia/cerebrospinal fluid , Adult , Chemokine CCL11/cerebrospinal fluid , Chemokines, CC/cerebrospinal fluid , Cross-Sectional Studies , Depression/cerebrospinal fluid , Fatigue/cerebrospinal fluid , Female , Humans , Male , Middle Aged
5.
J Trace Elem Med Biol ; 37: 1-7, 2016 Sep.
Article in English | MEDLINE | ID: mdl-27473826

ABSTRACT

Neuropathic pain affects 1-10% of the general population and is caused by a lesion or disease of the somatosensory nervous system. Spinal cord stimulation (SCS), a method where implanted electrodes stimulate the spinal cord, has been successfully used to treat drug-resistant neuropathic pain, but the mechanism of action is largely unknown. Studies show that SCS changes the protein levels in CSF (cerebrospinal fluid) of pain patients. Several neurological conditions have been shown to alter the elemental composition of CSF. Therefore changes in the levels of ions and trace elements in the CSF may correspond to SCS use. This study used ICP-MS (Inductively coupled plasma mass spectrometry) and ICP-AES (Inductively coupled plasma atomic emission spectroscopy) to quantify 10 elements in CSF from chronic neuropathic pain patients using SCS. The element concentrations in CSF from patients with SCS treatment on/off, were measured. No effect on the element concentrations in CSF from treatment with SCS could be detected. Also, the elemental concentrations in pooled CSF from patients without chronic neuropathic pain was determined and compared to the patients using SCS. The concentration of the elements Ca, Sr, Na, K, P, Mg and Ti were, significantly higher in patients compared to the CSF-control.


Subject(s)
Chronic Pain/cerebrospinal fluid , Spinal Cord Stimulation , Trace Elements/cerebrospinal fluid , Adolescent , Adult , Aged , Female , Humans , Male , Mass Spectrometry , Middle Aged , Spectrophotometry, Atomic , Young Adult
6.
Pain Pract ; 16(2): 183-203, 2016 Feb.
Article in English | MEDLINE | ID: mdl-25353056

ABSTRACT

Chronic pain is a prevalent and debilitating condition, conveying immense human burden. Suffering is caused not only by painful symptoms, but also through psychopathological and detrimental physical consequences, generating enormous societal costs. The current treatment armamentarium often fails to achieve satisfying pain relief; thus, research directed toward elucidating the complex pathophysiological mechanisms underlying chronic pain syndromes is imperative. Central neuroimmune activation and neuroinflammation have emerged as driving forces in the transition from acute to chronic pain, leading to central sensitization and decreased opioid efficacy, through processes in which glia have been highlighted as key contributors. Under normal conditions, glia exert a protective role, but in different pathological states, a deleterious role is evident--directly and indirectly modulating and enhancing pain transmission properties of neurons, and shaping synaptic plasticity in a dysfunctional manner. Cytokines and neurotrophic factors have been identified as pivotal mediators involved in neuroimmune activation pathways and cascades in various preclinical chronic pain models. Research confirming these findings in humans has so far been scarce, but this comprehensive review provides coherent data supporting the clear association of a mechanistic role of altered central cytokines and neurotrophic factors in a number of chronic pain states despite varying etiologies. Given the importance of these factors in neuropathic and inflammatory chronic pain states, prospective therapeutic strategies, and directions for future research in this emerging field, are outlined.


Subject(s)
Chronic Pain/cerebrospinal fluid , Cytokines/cerebrospinal fluid , Nerve Growth Factors/cerebrospinal fluid , Neuralgia/cerebrospinal fluid , Humans
7.
J Pain ; 16(5): 436-44, 2015 May.
Article in English | MEDLINE | ID: mdl-25659204

ABSTRACT

UNLABELLED: Descending pain inhibition is an endogenous pain control system thought to depend partially on the activation of bulbospinal monoaminergic pathways. Deficits in descending pain inhibition have been reported in numerous human chronic pain conditions, but there is currently no consensus regarding the neurochemical correlates responsible for this deficit. The aims of this study were to 1) assess the efficacy of descending pain inhibition in pain-free and chronic pain subjects, 2) screen for changes in centrally (ie, cerebrospinal fluid) and peripherally (ie, plasma) acting monoamine concentrations, and 3) explore the relationship between descending pain inhibition and monoamine neurotransmitter concentrations. Our results clearly show a deficit in pain inhibition, along with lower plasma norepinephrine and metanephrine concentrations in chronic pain subjects, compared to pain-free subjects. No differences were found in cerebrospinal fluid neurotransmitter concentrations. Finally, our results revealed a positive relationship between blood-bound norepinephrine and metanephrine concentrations and the efficacy of descending pain inhibition. Thus, basal monoamine levels in blood were related to descending pain inhibition. This finding supports the emerging idea that individual differences in descending pain inhibition may be linked to individual differences in peripheral processes, such as monoamines release in blood, which are possibly related to cardiovascular control. PERSPECTIVES: This article presents psychophysical and neurochemical findings that indicate that the latent potential of descending pain inhibitory responses is associated with differential activity in peripheral processes governed by monoamine neurotransmitter release, bringing insights into the relationship between descending pain inhibition and cardiovascular control in humans.


Subject(s)
Chronic Pain , Neural Inhibition/physiology , Neurotransmitter Agents , Pain Perception/physiology , Transurethral Resection of Prostate , Aged , Chronic Pain/blood , Chronic Pain/cerebrospinal fluid , Humans , Male , Middle Aged , Neural Pathways/physiology , Neurotransmitter Agents/blood , Neurotransmitter Agents/cerebrospinal fluid
8.
Neurochem Int ; 82: 1-9, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25661513

ABSTRACT

Endomorphin-2 (EM2) and Substance P (SP) exert suppressive and facilitative influences upon nociception, respectively. Although EM2 and SP were often co-expressed in single neurons in dorsal root ganglion (DRG), it is still unknown if and how the nociception-suppressive influences of EM2 might be exerted upon nociception-facilitative effects of SP in the DRG neurons. We examined these issues in the inflammatory pain model rats produced by subcutaneous injection of the complete Freund's adjuvant into the hind paw. The paw withdrawal threshold for mechanical allodynia was measured. Changes of EM2 and SP release were estimated by measuring intrathecal levels of EM2 and SP through in vivo microdialysis analysis of cerebrospinal fluid. The mechanical allodynia was dose-dependently attenuated by intrathecal injection of EM2 or a neurokinin-1 receptor antagonist, and facilitated by intrathecal injection of SP or a mu-opioid receptor (MOR) antagonist. Importantly, intrathecal level of SP was found to be lowered by intrathecal injection of EM2. Morphologically, colocalization of EM2-, MOR- and SP-immunoreactivity in single DRG neurons was observed by immunofluorescent histochemistry, and co-expression of EM2 and SP in large, dense-cored presynaptic vesicles in primary afferents, as well as localization of MOR on pre- and postsynaptic membrane in spinal dorsal horn, was also confirmed electron miscroscopically. Thus, the results indicated that analgesic influences of EM2 upon inflammatory pain might be exerted through suppression of SP release, supporting the assumptions that binding of EM2 to presynaptic MOR might induce such effects.


Subject(s)
Arthritis, Experimental/physiopathology , Chronic Pain/physiopathology , Hyperalgesia/physiopathology , Nociception/physiology , Oligopeptides/physiology , Receptors, Presynaptic/drug effects , Spinal Cord/physiopathology , Substance P/metabolism , Animals , Chronic Pain/cerebrospinal fluid , Chronic Pain/etiology , Ganglia, Spinal/physiopathology , Hyperalgesia/cerebrospinal fluid , Hyperalgesia/etiology , Injections, Spinal , Male , Microdialysis , Microscopy, Electron , Neurokinin-1 Receptor Antagonists/administration & dosage , Neurokinin-1 Receptor Antagonists/pharmacology , Neurons, Afferent/physiology , Oligopeptides/administration & dosage , Oligopeptides/cerebrospinal fluid , Oligopeptides/pharmacology , Rats , Rats, Sprague-Dawley , Receptors, Opioid, mu/antagonists & inhibitors , Receptors, Opioid, mu/physiology , Receptors, Presynaptic/physiology , Spinal Cord/ultrastructure , Spinal Cord Dorsal Horn/physiopathology , Stress, Mechanical , Substance P/cerebrospinal fluid , Tryptophan/administration & dosage , Tryptophan/analogs & derivatives , Tryptophan/pharmacology
9.
Pain Med ; 15(1): 111-9, 2014 Jan.
Article in English | MEDLINE | ID: mdl-24118997

ABSTRACT

OBJECTIVE: Pain medicine still lacks mechanism-specific biomarkers to guide diagnosis and treatment, and defective top-down modulation is an important factor in the pathophysiology of chronic pain conditions. Using modern analytical tools and advanced multivariate statistical analysis, the aim of this study was to revisit two classical potential biomarkers of pro- and anti-nociception in humans (substance P and beta-endorphin), focusing particularly on the cerebrospinal fluid (CSF). DESIGN: Cross-sectional, comparative, observational study. SUBJECTS: Patients with chronic, post-traumatic and/or post-surgical, neuropathic pain refractory to conventional treatment (N = 15) and healthy controls (N = 19) were included. METHODS: Samples were taken from CSF and blood, and levels of substance P and beta-endorphin were investigated using a Luminex technology kit. RESULTS: We found low levels of beta-endorphin in the CSF of neuropathic pain patients (66 ± 11 pcg/mL) compared with healthy controls (115 ± 14 pcg/mL) (P = 0.017). Substance P levels in the CSF did not differ (20 ± 2 pcg/mL, 26 ± 2, P = 0.08). However, our multivariate data analysis showed that belonging to the patient group was associated with low levels of both substances in the CSF. A higher correlation between the levels of beta-endorphin and substance P in CSF was found in healthy controls than in patients (rs = 0.725, P < 0.001 vs. rs = 0.574, P = 0.032). CONCLUSIONS: Patients with chronic neuropathic pain due to trauma or surgery had low levels of beta-endorphin in the CSF. We speculate that this could indicate a defective top-down modulation of pain in chronic neuropathic pain. Our results also illustrate the importance of taking a system-wide, multivariate approach when searching for biomarkers.


Subject(s)
Chronic Pain/cerebrospinal fluid , Neuralgia/cerebrospinal fluid , beta-Endorphin/cerebrospinal fluid , Adult , Analgesics/therapeutic use , Biomarkers/blood , Biomarkers/cerebrospinal fluid , Chronic Pain/blood , Chronic Pain/drug therapy , Chronic Pain/physiopathology , Clinical Trials as Topic/statistics & numerical data , Cross-Sectional Studies , Female , Humans , Male , Middle Aged , Neuralgia/blood , Neuralgia/drug therapy , Neuralgia/physiopathology , Pain, Intractable/blood , Pain, Intractable/cerebrospinal fluid , Pain, Intractable/drug therapy , Pain, Intractable/physiopathology , Pain, Postoperative/blood , Pain, Postoperative/cerebrospinal fluid , Pain, Postoperative/drug therapy , Pain, Postoperative/physiopathology , Substance P/blood , Substance P/cerebrospinal fluid , beta-Endorphin/blood
10.
Clin J Pain ; 30(4): 331-9, 2014 Apr.
Article in English | MEDLINE | ID: mdl-23887333

ABSTRACT

OBJECTIVES: Although high abundant cystatin c (CysC) in cerebrospinal fluid (CSF) is well known, its ambiguous role associated with pain still remains unclear. This study evaluated the effects of intrathecal CysC content from chronic pain caused by osteoarthritis (OA) and the novel relationship with matrix metalloproteinases 2 and 9 (MMP2 and MMP9) in CSF. METHODS: Samples of CSF were obtained from 8 elderly patients (65 y and above) with OA with lower limb pain for at least 6 months (OA group) and 8 sex-matched and age-matched relatively healthy elderly individuals without any pain problems (control group). The intrathecal CysC, MMP2, and MMP9 were examined by Western blotting. The analysis of CysC cleavage under different conditions was performed through silver staining and using mass-spectroscopy (SELDI-TOF) on 2 groups. RESULTS: Expression of full-length CysC and pro-MMP2 proteins showed statistically significant upregulation (P=0.0004 vs. 0.03), and expression of MMP9 protein showed downregulation (P=0.007) in the OA group. Both MMP9 and MMP2 initiated the mechanism for full-length CysC cleavage only in the presence of CSF. However, MMP9 showed greater ability than MMP2 for CysC cleavage in control and OA groups in sliver staining. Incubation of CSF with the MMP9 inhibitor led to the suppression of CysC cleavage in SELDI-TOF. DISCUSSION: These findings provide the first in vivo evidence on a relationship between CysC and gelatinases (MMP2 and MMP9), and could facilitate further investigation of novel interactions among these proteins within the proteomics field, especially protein-protein interactions involved in pain.


Subject(s)
Chronic Pain/cerebrospinal fluid , Chronic Pain/etiology , Cystatin C/cerebrospinal fluid , Matrix Metalloproteinase 9/cerebrospinal fluid , Osteoarthritis/complications , Signal Transduction/physiology , Aged , Aged, 80 and over , Case-Control Studies , Female , Humans , Male , Middle Aged , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization , Up-Regulation/physiology
11.
Neurology ; 80(1): 106-17, 2013 Jan 01.
Article in English | MEDLINE | ID: mdl-23267031

ABSTRACT

OBJECTIVES: We conducted a systematic review of the literature with meta-analysis to determine whether complex regional pain syndrome (CRPS) is associated with a specific inflammatory profile and whether this is dependent on the duration of the condition. METHODS: Comprehensive searches of the literature using MEDLINE, Embase, Scopus, Web of Science, and reference lists from published reviews identified articles that measured inflammatory factors in CRPS. Two independent investigators screened titles and abstracts, and performed data extraction and risk of bias assessments. Studies were subgrouped by medium (blood, blister fluid, and CSF) and duration (acute and chronic CRPS). Where possible, meta-analyses of inflammatory factor concentrations were performed and pooled effect sizes were calculated using random-effects models. RESULTS: Twenty-two studies were included in the systematic review and 15 in the meta-analysis. In acute CRPS, the concentrations of interleukin (IL)-8 and soluble tumor necrosis factor receptors I (sTNF-RI) and II (sTNF-RII) were significantly increased in blood. In chronic CRPS, significant increases were found in 1) TNFα, bradykinin, sIL-1RI, IL-1Ra, IL-2, sIL-2Ra, IL-4, IL-7, interferon-γ, monocyte chemoattractant protein-1 (MCP-1), and sRAGE (soluble receptor for advanced glycation end products) in blood; 2) IL-1Ra, MCP-1, MIP-1ß, and IL-6 in blister fluid; and 3) IL-1ß and IL-6 in CSF. Chronic CRPS was also associated with significantly decreased 1) substance P, sE-selectin, sL-selectin, sP-selectin, and sGP130 in blood; and 2) soluble intercellular adhesion molecule-1 (sICAM-1) in CSF. Most studies failed to meet 3 or more of our quality criteria. CONCLUSION: CRPS is associated with the presence of a proinflammatory state in the blood, blister fluid, and CSF. Different inflammatory profiles were found for acute and chronic cases.


Subject(s)
Complex Regional Pain Syndromes/diagnosis , Inflammation Mediators/metabolism , Acute Pain/blood , Acute Pain/cerebrospinal fluid , Acute Pain/diagnosis , Blister/metabolism , Chronic Pain/blood , Chronic Pain/cerebrospinal fluid , Chronic Pain/diagnosis , Complex Regional Pain Syndromes/blood , Complex Regional Pain Syndromes/cerebrospinal fluid , Humans
SELECTION OF CITATIONS
SEARCH DETAIL
...